Blood News and Research

RSS

New anti-angiogenic therapy can lead to tumour growth inhibition

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a natural protein first discovered at QUB. Anti-angiogenics prevent the growth of new blood vessels in tumours and starve them of nutrients, leading to inhibition of tumour growth.

4 Apr 2011

Catheter Connections presents DualCap device clinical data against CRBSI at SHEA meeting

In the ongoing fight against costly and potentially fatal catheter related bloodstream infections, landmark clinical data presented at the 21st Annual Scientific Meeting of the Society for Healthcare Epidemiology of America demonstrates that both the exposed end of IV administration sets and catheter luer access valves are colonized by the microbes that cause CRBSI.

4 Apr 2011

Routine periodic fasting can reduce risk of coronary heart disease

Fasting has long been associated with religious rituals, diets, and political protests. Now new evidence from cardiac researchers at the Intermountain Medical Center Heart Institute demonstrates that routine periodic fasting is also good for your health, and your heart.

4 Apr 2011

New research reveals potential treatment for HO in children, soldiers

Promising new research reveals a potentially highly effective treatment for heterotopic ossification, a painful and often debilitating abnormal buildup of bone tissue. HO comes in two main forms—one that appears in children and is congenital, another that strikes wounded military personnel and surgery patients and is triggered by severe injuries and wounds.

4 Apr 2011

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Highly exciting new data presented today at the International Liver Congress found Pegylated Interferon-lambda shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha, the current standard of care in chronic HCV.

4 Apr 2011

Scientists confirm metabolic syndrome may raise risk of liver cancer

Scientists have confirmed that metabolic syndrome, a constellation of conditions that increases the risk of heart disease and diabetes, may also increase the risk of the two most common types of liver cancer, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Non-invasive catheterization can lead to positive outcomes in elderly patients with stenosis

A major new study presented today at the yearly scientific meeting of the American College of Cardiology (ACC) in New Orleans shows conclusively that replacing defective aortic valves in elderly patients through non-invasive "catheterization" – rather than through much more invasive open-heart surgery – leads to significantly better outcomes.

4 Apr 2011

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

SMT Research and Development Ltd. of Herzliya Pituach, Israel announced today a significant investment by OrbiMed Advisors LLC. SMT is finalizing the development of a novel embolic protection device designed for use during Transcatheter Aortic Valve Implantation procedures.

4 Apr 2011

Positive results from Abbott's ABSORB device trial in coronary artery disease

Abbott today announced positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the world's first drug eluting Bioresorbable Vascular Scaffold for the treatment of coronary artery disease.

4 Apr 2011

Study: Antidepressants can thicken arteries and lead to heart disease

Antidepressant use has been linked to thicker arteries, possibly contributing to the risk of heart disease and stroke, in a study of twin veterans. The data is being presented Tuesday, April 5 at the American College of Cardiology meeting in New Orleans.

4 Apr 2011

QIAGEN to acquire Cellestis

QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately A$341 million in cash, providing QIAGEN with access to a novel "pre-molecular" technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.

From QIAGEN Manchester Limited 4 Apr 2011

Lack of vitamin D can lead to impaired vascular health

A lack of vitamin D, even in generally healthy people, is linked with stiffer arteries and an inability of blood vessels to relax, research from the Emory/Georgia Tech Predictive Health Institute has found.

4 Apr 2011

Antidepressants may increase heart attack or stroke risk in men: Study

...

3 Apr 2011

New heart valve procedure helpful for the elderly: Study

Researchers revealed this Sunday a new heart valve that can be implanted without surgery. The device may hold promise for tens of thousands of elderly patients who might not survive a standard valve-replacement operation.

3 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Two experts to comment on new transcatheter heart valve studies

New transcatheter heart valve studies will be presented at the American College of Cardiology meeting in New Orleans on April 3 and 4. The studies compare patient outcomes from minimally invasive catheter procedures with those from open-heart surgery.

2 Apr 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Prevalence of NAFLD in US expected to increase by 50% in 2030: Study

According to new data presented today at the International Liver CongressTM, the United States could soon be faced with an epidemic of Non-Alcoholic Fatty Liver Disease, one of the major contributing factors of chronic liver disease, considered as one of the major causes of morbidity and mortality worldwide.

2 Apr 2011

Report shows a continued decline in diagnoses, deaths for many types of cancers

Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection.

2 Apr 2011

Diabetes testing among poor adults plunged 23% in 2007: AHRQ

The proportion of poor adults age 40 and over with diabetes who had their blood sugar, eyes and feet examined at least once a year dropped from 39 percent to 23 percent between 2002 and 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

2 Apr 2011